Literature DB >> 20473788

Small molecule inhibitors of the PI3-kinase family.

Zachary A Knight1.   

Abstract

The PI3-K family is one of the most intensely pursued classes of drug targets. This chapter reviews some of the chemical and structural features that determine the selectivity of PI3-K inhibitors, by focusing on a few key compounds that have been instrumental in guiding our understanding of how to design drugs against this family.

Mesh：

Substances：

Year:  2010        PMID： 20473788     DOI： 10.1007/82_2010_44

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN： 0070-217X            Impact factor:   4.291


  9 in total

1.  Spatiotemporal expression of foxo4, foxo6a, and foxo6b in the developing brain and retina are transcriptionally regulated by PI3K signaling in zebrafish.

Authors:  Sheng-Jia Lin; Ming-Chang Chiang; Hung-Yu Shih; Kun-Chun Chiang; Yi-Chuan Cheng
Journal:  Dev Genes Evol       Date:  2017-02-02       Impact factor: 0.900

2.  MicroRNAs are critical regulators of tuberous sclerosis complex and mTORC1 activity in the size control of the Xenopus kidney.

Authors:  Daniel Romaker; Vikash Kumar; Débora M Cerqueira; Ryan M Cox; Oliver Wessely
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-14       Impact factor: 11.205

3.  Endosomal Phosphatidylinositol 3-Kinase Is Essential for Canonical GPCR Signaling.

Authors:  Yasunori Uchida; Florentine U Rutaganira; Damien Jullié; Kevan M Shokat; Mark von Zastrow
Journal:  Mol Pharmacol       Date:  2016-11-07       Impact factor: 4.436

4.  Linker for activation of T-cell family member2 (LAT2) a lipid raft adaptor protein for AKT signaling, is an early mediator of alkylphospholipid anti-leukemic activity.

Authors:  Carolina H Thomé; Guilherme A dos Santos; Germano A Ferreira; Priscila S Scheucher; Clarice Izumi; Andreia M Leopoldino; Ana Maria Simão; Pietro Ciancaglini; Kleber T de Oliveira; Alice Chin; Samir M Hanash; Roberto P Falcão; Eduardo M Rego; Lewis J Greene; Vitor M Faça
Journal:  Mol Cell Proteomics       Date:  2012-09-22       Impact factor: 5.911

5.  A genome-wide RNAi screen identifies potential drug targets in a C. elegans model of α1-antitrypsin deficiency.

Authors:  Linda P O'Reilly; Olivia S Long; Murat C Cobanoglu; Joshua A Benson; Cliff J Luke; Mark T Miedel; Pamela Hale; David H Perlmutter; Ivet Bahar; Gary A Silverman; Stephen C Pak
Journal:  Hum Mol Genet       Date:  2014-05-16       Impact factor: 6.150

Review 6.  Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors.

Authors:  S J Shuttleworth; F A Silva; A R L Cecil; C D Tomassi; T J Hill; F I Raynaud; P A Clarke; P Workman
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

Review 7.  Routes and mechanisms of extracellular vesicle uptake.

Authors:  Laura Ann Mulcahy; Ryan Charles Pink; David Raul Francisco Carter
Journal:  J Extracell Vesicles       Date:  2014-08-04

Review 8.  Exosome-derived microRNAs in cancer metabolism: possible implications in cancer diagnostics and therapy.

Authors:  Marco Tomasetti; Wan Lee; Lory Santarelli; Jiri Neuzil
Journal:  Exp Mol Med       Date:  2017-01-20       Impact factor: 8.718

9.  Combining metformin and nelfinavir exhibits synergistic effects against the growth of human cervical cancer cells and xenograft in nude mice.

Authors:  Chenglai Xia; Ruihong Chen; Jinman Chen; Qianqian Qi; Yanbin Pan; Lanying Du; Guohong Xiao; Shibo Jiang
Journal:  Sci Rep       Date:  2017-03-02       Impact factor: 4.379
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.